Login to Your Account



I.V. Vernakalant Still 'Up in the Air'

Cardiome Gets Much-Needed Deal in $800M Merck Alliance

By Jennifer Boggs


Friday, April 10, 2009
Shares of Cardiome Pharma Corp. shot up 25 percent after it scored a crucial partnership for its late-stage atrial fibrillation drug, vernakalant. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription